lymphoid tissue and alveolar macrophages. IPF patient lung section analysis revealed an absence of TRAIL expression compared to controls. IPF patients had significantly lower serum levels of TRAIL than controls which inversely correlated with TLCO (% predicted) and positively correlated with survival from diagnosis.

**Conclusions** We demonstrated that the neutrophil inflammatory response to bleomycin is increased in TRAIL−/− compared with wild-type mice and that this finding is associated with increased collagen deposition. We also demonstrated reduced pulmonary and systemic expression of TRAIL in IPF; which correlates with worse pulmonary function and clinical outcome. This data suggests TRAIL may have biomarker potential and therapeutic benefit in pulmonary fibrosis.

**S112 TNF-R1 Ubiquitous Scaffolding and Signalling Protein (TRUSS) is a Regulator of TNF-α Induced NF-κ-B Activation**

doi:10.1136/thoraxjnl-2011-201054b.112

1 A Langton, 1 Heran, 2 S Farrow, 3 D W Riches, 1 E R Chilvers, 1 H Parfrey. 1 University of Cambridge, Cambridge, UK; 2GlaxoSmithKline, Stevenage, UK; 3National Jewish Health, Denver, USA

The pleotropic cytokine TNFα plays a key role in the pathogenesis of many chronic inflammatory lung diseases, particularly sarcoidosis, asthma and COPD. Due to its broad spectrum of activity however, current anti-TNFα therapies are of limited efficacy in these conditions and are associated with an increased risk of infection and malignancy. Interaction of TNFα with its cognate receptor, TNF-R1 initiates a signalling cascade that leads ultimately to the phosphorylation of the transcription factor NF-κB. This allows NF-κB to shuttle in a co-ordinated manner between the cytoplasm and the nucleus, leading to the up-regulation of genes that are key to cellular inflammatory and apoptotic responses. We propose that the novel TNF-R1 interacting protein TRUSS (TNF-R1 Ubiquitous Scaffolding and Signalling protein), which interacts with members of the TNF-R1 signalling cascade, may regulate this process. A549 cells, which express high levels of endogenous TRUSS, were transfected transiently with siRNA, which resulted in 80±14% (mean±SEM, n=16) knockdown of TRUSS mRNA. TRUSS deficient cells demonstrated a profound early (<1 h) defect in the nuclear translocation of p50/p65 subunits following TNFα stimulation (p<0.05, n=3). As a consequence, in the absence of TRUSS, p50, its precursor phospho-p105, and phospho-p65 were retained in the cytoplasm in these cells following TNFα stimulation. Furthermore, TRUSS depletion caused a reduction in TNFα stimulated NF-κB (p<0.01, n=7) and AP-1 (p<0.01, n=6) luciferase reporter activity; this was associated with a decrease in interleukin 6, RANTES, G-CSF and GM-CSF (p<0.05, n=6) mRNA and protein expression while MCP-1, CXCL5 and IL-8 were not affected. Although TRUSS depleted cells displayed impaired up-regulation of IL6a mRNA in response to TNFα stimulation, the protein response was intact. Upstream signalling molecules TNFR1, TRADD, TRAF2 and RIP were unaffected by TRUSS knockdown. In conclusion, these data suggest a novel role for TRUSS as a scaffold protein involved in the initial nuclear translocation of p50/p65 NF-κB subunits, which regulates the early pro-inflammatory response to TNFα. Hence TRUSS may represent a more selective therapeutic target for modulating TNFα functions.

**S113 The Influenza Virus Activates TGFβ via an αVβ6-Integrin Mediated Pathway**

doi:10.1136/thoraxjnl-2011-201054b.113

1 A Stavrou, 1 L Jolly, 2 J P Porte, 2 P W Weinreb, 1 A T Tatler, 1 A J John, 1 A K Knox, 1 S V Violet, 2 H Hussel, 1 S K Kuchipudi, 1 S D Dunham, 2 G J Jenkins. 1University of Nottingham, Nottingham, UK; 2Biogen Idec Inc, Cambridge; 3Imperial College London, London, UK

**Introduction and Objectives** Idiopathic pulmonary fibrosis is a chronic progressive lung disease of unknown cause. Its pathogenesis is poorly understood but activation of latent TGFβ on lung epithelium is an important factor. TGFβ must be activated, as it is secreted in a latent complex with its propeptide, the latency associated peptide, and the αvβ6 integrin is a key activator in the lung. The Influenza A virus is a single-stranded segmented RNA virus that infects epithelial cells leading to cell death and injury. Toll-like receptors (TLRs) detect pathogens, such as influenza. TLR3 activation has been found to increase RhoA activity. We previously showed that Rhoa is a key intermediary in αvβ6 integrin-mediated TGFβ activation. The aim of this study is to investigate whether influenza can activate TGFβ and stimulate TLR3 leading to activation of TGFβ through the αvβ6 integrin in epithelial cells.

**Materials and Methods** Immortalised human bronchial epithelial cells (iHBECS) were infected with influenza A (H2N3) virus at a multiplicity of infection 1 with, or without, the αvβ6 blocking antibody 6.5G9. iHBECs were also stimulated with the synthetic TLR3 ligand poly(I:C). TGFβ activity was determined by: (1) immunoblotting for phosphorylated (phospho-) Smad2, and (2) Transformed mink lung cells (TMLC)-iHBEC cocultures. Infection efficiency was measured by Interferon β mRNA levels by real-time qPCR.

**Results** Infection with H2N3 and stimulation with poly(I:C) led to increase in phospho-smad2 and luciferase activity in coculture indicating increase in TGFβ activation levels in a dose- and time-dependent manner. In both cases this was blocked with the addition of 6.5G9. qPCR data following infection showed increased IFNβ and PAI-1, indicating the ability of the virus to infect the cells and activate TGFβ.

**Conclusions** Influenza infection and poly(I:C) activates TGFβ in iHBECs in an αvβ6 integrin dependent manner. The data suggests a novel mechanism by which influenza infection of epithelial cells may promote lung fibrosis.

**S114 Lymphatic Vessel Distribution in Fibrotic Lung Diseases**

doi:10.1136/thoraxjnl-2011-201054b.114

1 E A Renzoni, 2 E Weber, 2 E Szajo, 2 A Rossi, 1 A U Wells. 1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK; 2Molecular Medicine Section, Department of Neuroscience, University of Siena, Siena, Italy

Relatively little is known on lymphatic vessel remodelling in lung fibrosis, and whether differences in lymphatic distribution underlie the worse survival seen in idiopathic pulmonary fibrosis, compared to the other fibrotic interstitial pneumonias. Lymphatic vessel remodelling and a deficit in lymphatic clearance could lead to prolonged exposure to pathogenic antigens and/or pro-inflammatory/pro-fibrotic mediators in the alveolar-interstitial space. In this study, we compared lymphatic and blood vessel morphology in lung biopsies of six patients with idiopathic pulmonary fibrosis (with usual interstitial pneumonia pattern-UIP), six patients with fibrotic non-specific interstitial pneumonia associated with sarcodermia (NSIP), five patients with fibrotic organising pneumonia (FOP) and five controls (normal lung peripheral to resected cancer). Consecutive sections were stained with Movat’s pentachrome and with double immunostaining for von Willebrand factor (blood vessels) and for podoplanin (lymphatic specific marker D2-40) (see Abstract S114 figure 1). Area, perimeter and position were recorded for all lymphatic vessels and for blood vessels with a diameter >15 μm, to be sure to exclude capillaries. In the three disease groups, blood